Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Observational Post-Authorisation Safety Study of Asenapine (Sycrest) (OBSERVA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Professor Saad Shakir, Drug Safety Research Unit, Southampton, UK
ClinicalTrials.gov Identifier:
NCT01734278
First received: November 22, 2012
Last updated: October 27, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2017
  Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)